ARCHIVES

FDA Approves Gemzar For Ovarian Cancer, Contradicting ODAC Recommendation; Continues Agency Trend to Recognize Progression-Free Survival As An Endpoint.

This article is from The Cancer Letter archive.

Vol. 32 No. 28 | July 21, 2006

Download PDF Visit The Full Archive

Related Articles

DRG Executives Names By DeVita as Director Of DEA; Other Sections Reportedly Made, Not Yet Approved

July 31, 1981

ACS Division Help Fund Some CIS Offices

September 13, 1985

Group Chairmen Reject DCT’s Agenda For Clinical Trials Review, demand Right To Select Speakers

June 30, 1978

FDA Needs Staff, Funds But first Must Determine Priorities, GAO Says

November 17, 1989

NIH “RFA Game” Defeats Purpose Of OAM, Advisor Says

September 30, 1994

John Niederhuber Named Acting NCI Director.

June 2, 2006